Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 118 participants.
Also called NCT03535935
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 118 participants
- Sponsor
- Registry
-
NCT03535935
-
- Other papers using this trial's data
- Add-on astragalus in type 2 diabetes and chronic kidney disease: A multi-center, assessor-blind, randomized controlled trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Hong Kong SAR China
- Registry status
- Unknown status
Technical summary
Registry record NCT03535935. Randomized; single masking; primary purpose treatment. Start 2018-07-01 (actual); primary completion 2022-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease
- Acronym
- READY
- Condition
- Diabetic Nephropathies
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- Astragalus Powder
- Intervention (Other)
- Routine medical care (active comparator)
- Lead sponsor
- The University of Hong Kong
Record details
- Record id
cardio:ct-nct03535935- Content hash
426f1e255f9ab38999cff9fc7a4d4e133e91a228cf3fff4fca702d9022c01a13